JP2002522512A5 - - Google Patents

Download PDF

Info

Publication number
JP2002522512A5
JP2002522512A5 JP2000564666A JP2000564666A JP2002522512A5 JP 2002522512 A5 JP2002522512 A5 JP 2002522512A5 JP 2000564666 A JP2000564666 A JP 2000564666A JP 2000564666 A JP2000564666 A JP 2000564666A JP 2002522512 A5 JP2002522512 A5 JP 2002522512A5
Authority
JP
Japan
Prior art keywords
dextran
leptin
conjugate
moiety
moieties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000564666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002522512A (ja
JP4199421B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/018129 external-priority patent/WO2000009165A1/en
Publication of JP2002522512A publication Critical patent/JP2002522512A/ja
Publication of JP2002522512A5 publication Critical patent/JP2002522512A5/ja
Application granted granted Critical
Publication of JP4199421B2 publication Critical patent/JP4199421B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000564666A 1998-08-10 1999-08-10 デキストラン−レプチン結合体、医薬組成物および関連方法 Expired - Lifetime JP4199421B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9619498P 1998-08-10 1998-08-10
US60/096,194 1998-08-10
US37068499A 1999-08-09 1999-08-09
US09/370,684 1999-08-09
PCT/US1999/018129 WO2000009165A1 (en) 1998-08-10 1999-08-10 Dextran-leptin conjugates, pharmaceutical compositions and related methods

Publications (3)

Publication Number Publication Date
JP2002522512A JP2002522512A (ja) 2002-07-23
JP2002522512A5 true JP2002522512A5 (enExample) 2006-10-05
JP4199421B2 JP4199421B2 (ja) 2008-12-17

Family

ID=26791397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000564666A Expired - Lifetime JP4199421B2 (ja) 1998-08-10 1999-08-10 デキストラン−レプチン結合体、医薬組成物および関連方法

Country Status (9)

Country Link
EP (1) EP1107793B1 (enExample)
JP (1) JP4199421B2 (enExample)
AT (1) ATE280588T1 (enExample)
AU (1) AU5347099A (enExample)
CA (1) CA2337667C (enExample)
DE (1) DE69921486T2 (enExample)
ES (1) ES2228082T3 (enExample)
PT (1) PT1107793E (enExample)
WO (1) WO2000009165A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
ATE323766T1 (de) * 1999-02-12 2006-05-15 Amgen Inc Glykosylierte leptinzusammensetzungen und zugehörige verfahren
GB0116860D0 (en) 2001-07-10 2001-09-05 Univ Montfort Gel compositions
EP1744786A2 (en) * 2004-03-23 2007-01-24 Amgen Inc. Chemically modified protein compositions and methods
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
WO2009143380A2 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
AU2009313562B2 (en) 2008-11-04 2012-11-15 Neurotez, Inc. Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
DK3074033T3 (en) 2013-11-26 2019-02-11 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
MX2019002818A (es) 2016-09-12 2019-08-29 Aegerion Pharmaceuticals Inc Metodos para detectar anticuerpos neutralizantes anti-leptina.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006816A1 (en) * 1995-08-17 1997-02-27 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
WO1997038014A1 (en) * 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods

Similar Documents

Publication Publication Date Title
JP2002527052A5 (enExample)
JP2002522512A5 (enExample)
US6617306B2 (en) Carrier for in vivo delivery of a therapeutic agent
CA2345027A1 (en) Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
JP2008524117A5 (enExample)
JP2011524420A5 (enExample)
MX2011003788A (es) Mutantes fgf21 y uso de los mismos.
JP2003505347A5 (enExample)
WO1994001460A1 (en) Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis
US20020147142A1 (en) Methods and reducing or maintaining reduced levels of blood lipids using OB protein compositions
JP2008540565A5 (enExample)
KR950701937A (ko) 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체(glucagon-like peptide and insulinotropin derivatives)
JP2005516885A5 (enExample)
JP2010518079A5 (enExample)
WO2000005260A1 (en) Peptide analogues of pacap
RU2007110981A (ru) Урокортин iii и его использование
JP2008518026A5 (enExample)
JP2006506097A5 (enExample)
JP2010513327A5 (enExample)
JP2003534287A5 (enExample)
JP2002525081A5 (enExample)
JP2009520758A5 (enExample)
EP1399108A4 (en) PREPARATION OF A THERAPEUTIC COMPOSITION
JP2009502803A5 (enExample)
WO1997038014A1 (en) Fibulin pharmaceutical compositions and related methods